Radiation combined with antiangiogenic and antivascular agents

被引:55
|
作者
O'Reilly, MS
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词
D O I
10.1016/j.semradonc.2005.08.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is critical for a number of physiologic and pathophysiologic processes, and angiogenesis inhibitors are now being used in the treatment of cancer. Although antiangiogenic agents offer great therapeutic potential, preclinical and clinical trial results suggest that these agents will have a delayed onset of activity and may only induce disease stabilization for patients with advanced malignancy. The use of radiation therapy for cancer is also associated with therapeutic challenges that are distinct from those that might be expected with antiangiogenic agents. Thus, the use of angiogenesis inhibitors in combination with radiation therapy should help to overcome the limitations of each leading to enhanced efficacy and diminished toxicity. The goal of this review is to provide an overview and discussion of the combination of angiogenesis inhibitors with radiation therapy. © 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条
  • [31] Understanding resistance to antiangiogenic agents
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2014, 13 (10) : 726 - 726
  • [32] Interferons as antiangiogenic agents.
    Lindner D.J.
    Current Oncology Reports, 2002, 4 (6) : 510 - 514
  • [33] Antiangiogenic agents in breast cancer
    Salter, John T.
    Miller, Kathy D.
    CANCER INVESTIGATION, 2007, 25 (07) : 518 - 526
  • [34] Quantification of Antiangiogenic and Antivascular Drug Activity by Kinetic Analysis of DCE-MRI Data
    Ferl, G. Z.
    Port, R. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (01) : 118 - 124
  • [35] Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?
    Soria, J. -C.
    Deutsch, E.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1247 - 1249
  • [36] Antiangiogenic and antivascular effects of a recombinant tumstatin-derived peptide in a corneal neovascularization model
    Esipov, Roman
    Beyrakhova, Ksenia
    Likhvantseva, Vera
    Stepanova, Evgenia
    Stepanenko, Vasily
    Kostromina, Maria
    Abramchik, Yulia
    Miroshnikov, Anatoly
    BIOCHIMIE, 2012, 94 (06) : 1368 - 1375
  • [37] Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials
    Leach, MO
    Brindle, KM
    Evelhoch, JL
    Griffiths, JR
    Horsman, MR
    Jackson, A
    Jayson, G
    Judson, IR
    Knopp, MV
    Maxwell, RJ
    McIntyre, D
    Padhani, AR
    Price, P
    Rathbone, R
    Rustin, G
    Tofts, PS
    Tozer, GM
    Vennart, W
    Waterton, JC
    Williams, SR
    Workman, P
    BRITISH JOURNAL OF RADIOLOGY, 2003, 76 : S87 - S91
  • [38] Diabetic Retinopathy and Antivascular Endothelial Growth Factor Agents
    Patel, Shriji
    Sternberg, Paul, Jr.
    JAMA OPHTHALMOLOGY, 2017, 135 (06) : 568 - 569
  • [39] Oxygen levels during antivascular, neoplastic and combined therapy
    Hansen-Algenstaedt, N
    Fukumura, D
    Stoll, B
    Padera, T
    Hicklin, DJ
    Jain, RK
    FASEB JOURNAL, 1999, 13 (04): : A26 - A26
  • [40] Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors
    Wang, Chunyu
    Rimner, Andreas
    Gelblum, Daphna Y.
    Flynn, Jessica
    Jackson, Andrew
    Yorke, Ellen
    Wu, Abraham J.
    JAMA ONCOLOGY, 2019, 5 (05) : 737 - 739